AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06033079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: For enrolled subjects assigned to the decision support arm, providers will receive prognostic information derived using our previously validated and best performing model. The decision support application will automatically calculate predicted risk for moderate (intensive care) and severe (respiratory failure or shock) outcomes using the parameters derived from the prognostic tool's regression equation. Outcome probabilities will be integrated into the decision support application and displayed within the EHR.
Study NCT03430921 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Enlighten™ Laser and a MLA Attachment
Description: Subjects will receive treatments with the Cutera enlighten laser with the Micro-Lens Array handpiece attachment.
Study NCT04892836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Resistance training (4 different exercises, leg press, leg extension, leg curl, and seated calf raises)
Study NCT02626507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: adenosine triphosphate (ATP) competitive, highly selective and potent inhibitor of pan-class I isoform phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3-K)
Study NCT02626507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faslodex
Description: Faslodex® (Fulvestrant) is a potent anti-estrogen drug that binds and degrades estrogen receptors (ERs).
Study NCT02626507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib (Ibrance®) is an orally active highly selective reversible inhibitor of cyclin-dependent kinase (CDK) 4 and CDK 6.
Study NCT02626507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex
Description: Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment.
Study NCT03355300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
Study NCT03565627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise app: 7 Minute Workout Challenge
Description: 7 Minute Workout Challenge by Fitness Guide Inc. combines aerobic and resistance training into short, 7 minute high intensity circuit training.
Study NCT03565627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Running app: One You Couch to 5K
Description: One You Couch to 5K by Public Health England is a popular app that aims to increase fitness by asking the user to follow a running programme with a goal to run for 30 min without break.
Study NCT03042507 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Description: The existing CBIT protocol includes a functional assessment procedure designed to identify relevant contextual variables (both antecedent and consequent) impacting tic expression and guide the development of an individualized behavioral program to neutralize these contextual influences in the service of tic reduction and psychoeducational component. Given the central role that negative social reactions typically play in tic exacerbation and maintenance, psychoeducation about tics is systematically provided to parents, siblings, and other caretakers and prominent individuals in the child's life. The other primary CBIT component, Habit Reversal Training (HRT), is used to weaken or eliminate the negative reinforcement cycle created by tic-contingent reduction in premonitory urge.
Study NCT04372277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar
Description: topical Enstilar foam
Study NCT01051427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgiflo
Description: Before to put a nasal catheter to stop nasal bleeding when anterior packing fails, we'll try to stop bleeding with Surgiflo.
Study NCT01051427 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal catheter
Description: In patients randomized not to put Surgiflo, we use a nasal catheter to try to stop nasal bleeding.
Study NCT03048422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: One 50 mg DTG tablet was administered orally once daily
Study NCT03048422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir alafenamide
Description: One fixed-dose combination tablet (FTC 200 mg/TAF 25 mg) was administered orally once daily
Study NCT03048422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: One fixed-dose combination tablet (FTC 200 mg/TDF 300 mg) was administered orally once daily
Study NCT03048422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz/emtricitabine/tenofovir disoproxil fumarate
Description: One fixed-dose combination tablet (EFV 600 mg/FTC 200 mg/TDF 300 mg) was administered orally once daily
Study NCT00800501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sNN0029
Description: Continuous ICV infusion at one of three dose levels
Study NCT00800501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous ICV infusion
Study NCT02922140 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pharmaceutical care service
Study NCT03116932 — intervention group
Intervention type: BEHAVIORAL
Intervention: PrEP knowledge and acceptability questionnaire
Description: This questionnaire consists of 187 items and evaluates socio-demographic variables, sex conducts, PrEP knowledge and PrEP acceptability.
Study NCT00939900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid (aclasta)
Description: Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period
Study NCT06162910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Daniels Water Swallow Test
Description: Clinical water swallow dysphagia screening
Study NCT06162910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Flexible Endoscopic Evaluation of Swallowing
Description: Endoscopic evaluation of swallowing function
Study NCT04391699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heated humidification
Description: heated humidification system
Study NCT00653003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: tablets, 20mg, single-dose
Study NCT00653003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARAVA
Description: Tablets, 20mg, single-dose
Study NCT00811772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: Implantation of one or more bare metal stent(s)
Study NCT00811772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Description: Implantation of one or more drug eluting stent(s)
Study NCT04156451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid resuscitation and furosemide administration (bolus and continuous) with central venous pressure target 8 - 10 mmHg
Description: Crystalloid loading or furosemide administration with the CVP target 8-10 mmHg is reached in septic shock patients
Study NCT04156451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid deresuscitation and furosemide administration (bolus and continuous) with central venous pressure target 0 - 4 mmHg
Description: active fluid removal with furosemide bolus and continuous or crystalloid loading until the CVP target 0-4 mmHg is reached in septic shock patients
Study NCT02883946 — intervention group
Intervention type: OTHER
Intervention: Data collection
Study NCT02484911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 5mg,twice a day orally on day 1 to day 4
Study NCT02484911 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aprepitant
Description: 125 mg capsule per oral, 1 hour before chemotherapy on day 1, 80 mg capsule daily in the morning during days 2 to 3.
Study NCT02484911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: 125 mg capsule per oral, 1 hour before chemotherapy on day 1, 80 mg capsule daily in the morning during days 2 to 3.
Study NCT02484911 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Palonosetron
Description: 0.25mg IV 30-60min before chemotherapy on day 1
Study NCT02484911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: 0.25mg IV 30-60min before chemotherapy on day 1
Study NCT02484911 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: 6mg IV on day 1 ，3.75mg IV on day 2 to 4
Study NCT02484911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 6mg IV on day 1 ，3.75mg IV on day 2 to 4
Study NCT04185688 — intervention group
Intervention type: OTHER
Intervention: Functional Reach Test
Description: The Functional Reach Test assesses balance by measuring the limits of stability while the patient reaches forwards as far as possible, having the arms in 90° flexion and without lifting the heels off the floor.
Study NCT01347151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The glidescope video laryngoscopy
Study NCT01347151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Pentax airwayscope
Study NCT01225484 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous femoral nerve block + periarticular infiltration
Description: Initial bolus of ropivacaine 5mg/ml 30mls into the femoral-nerve-catheter preoperatively. Periarticular infiltration of ropivacaine 2mg/ml 150 mls intraoperatively. Continuous perineural infusion of ropivacaine 2mg/ml at a rate of 6 mls/hr postoperatively. Rate can be adjusted to achieve optimal pain control and avoid motor blockade.
Study NCT01225484 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular and periarticular ropivacaine
Description: Periarticular infiltration of 150 mls ropivacaine 2mg/ml intraoperatively, intraarticular injection of 40 mls ropivacaine 2 mg/ml at skin closure followed by infusion of ropivacaine 2 mg/ml at a rate of 4 mls/hr delivered by an intraarticular catheter until the morning of postoperative day 3.
Study NCT04194099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS (Brain)
Description: Higher frequency (>5 Hz) trains increase cortical excitability.
Study NCT04194099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS rTMS (Brain)
Description: Intermittent theta burst stimulation (iTBS) is a newer rTMS approach.
Study NCT04194099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anode tsDCS (Spinal)
Description: Anodal tsDCS increased the spinal reflex amplitude, as well as corticospinal excitability.
Study NCT04194099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20 Hz current square-wave pulses (Spinal)
Description: Higher frequency (>5 Hz) of current increase cortical excitability.
Study NCT04194099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS (Spinal)
Description: Intermittent theta-burst stimulation (iTBS) is a newer approach. it may increase corticospinal excitability.
Study NCT04194099 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: with sham stimulation on brain and spinal.
Study NCT01116908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LifeStraw Family
Description: LifeStraw Family is a household water treatment technology that will be implemented in the household to improve drinking water quality
Study NCT04315519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic Exercise
Study NCT04071184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alofanib
Description: Five dose cohorts and expanded cohort will be included
Study NCT04559958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: tongue image
Description: capture tongue images by Automatic Tongue Diagnosis System
Study NCT03451773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1,200 or 500mg every 2 weeks by intravenous (IV) infusion
Study NCT03451773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard (1,000 mg/m\^2) or reduced (600 mg/m\^2 for 4 doses) intravenous (IV) once a week for first 4 weeks. Then, once weekly for 3 weeks with one week rest. Gemcitabine will be discontinued after 6 months of therapy
Study NCT01409135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-22M6E
Description: IV Infusion
Study NCT01409135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASG-22CE
Description: IV Infusion
Study NCT01028664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish
Description: 2-hour continuous IOP monitoring
Study NCT04766307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2
Description: Interleukin 2 (IL-2) is a pleiotropic cytokine that is produced after antigen activation and plays crucial roles in the immune response. IL-2 secreted by activated T cells is central to the development of an immune response to infection, promoting the differentiation and proliferation of lymphoid cells. This hydrophobic molecule and the various cytokines that it elicits regulates the behavior of T and B lymphocytes, monocytes/macrophages, natural killer (NK) cells, and neutrophils. IL-2 therapy regimens are expected to limit mycobacterial replication. Early clinical trials with IL-2 demonstrated that IL-2 immunotherapy may be useful in controlling infectious disease.
Study NCT04766307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin 2 (IL-2) is a pleiotropic cytokine that is produced after antigen activation and plays crucial roles in the immune response. IL-2 secreted by activated T cells is central to the development of an immune response to infection, promoting the differentiation and proliferation of lymphoid cells. This hydrophobic molecule and the various cytokines that it elicits regulates the behavior of T and B lymphocytes, monocytes/macrophages, natural killer (NK) cells, and neutrophils. IL-2 therapy regimens are expected to limit mycobacterial replication. Early clinical trials with IL-2 demonstrated that IL-2 immunotherapy may be useful in controlling infectious disease.
Study NCT00980200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 4 QD
Description: QD once daily
Study NCT00980200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 3 QD
Description: QD once daily
Study NCT00980200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study NCT00980200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2 QD
Description: QD once daily
Study NCT00980200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 1 BD
Description: BD twice daily
Study NCT02997761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV
Study NCT02997761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02065752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 100 mg
Description: Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
Study NCT02065752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR, 500 mg
Description: Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
Study NCT02065752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANA/MET XR FDC, Formulation 1, 50 mg/500 mg
Description: Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
Study NCT02065752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANA/MET XR FDC, Formulation 2, 50 mg/500 mg
Description: Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
Study NCT03762759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT03762759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT03762759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV
Study NCT03762759 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Gallium Ga68-labeled PSMA-11
Description: Given IV
Study NCT03762759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT03762759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT01535573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: 20 mg once per day for 9 weeks
Study NCT01535573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: 40 mg per day for 9 weeks
Study NCT01535573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg per day for 9 weeks
Study NCT01123863 — intervention group
Intervention type: OTHER
Intervention: Brigance Preschool Screen -II
Description: Three-year-old children with SCD who are followed at the St. Jude Children's Research Hospital Sickle Cell Center will be offered developmental screening with the Brigance Preschool Screen II during their regular clinic visits. Along with the screening test, socioeconomic data will be collected using a short questionnaire. Families will be asked to participate in this study by allowing us to collect their test results, medical information and socioeconomic data to compare with data collected from the control group. Parents who decline participation in this study will still be offered the Brigance Preschool Screen II as part of their child's clinical care.
Study NCT01123863 — intervention group
Intervention type: OTHER
Intervention: Brigance Preschool Screen -II
Description: Children in the Control Group will be given the Brigance preschool Screen-II Screening at the daycare they attend. The STARR coordinators have selected four daycare centers that have agreed to serve as control group sites. The family will be asked not to respond or aid the child during the assessment. One parent/guardian will fill out the Socioeconomic Data Collection Form while the examiner works with the child.~The screening requires the child to give both verbal and non-verbal responses. The examiner records responses on the Three-Year-Old Child Data Sheet for the Brigance Preschool Screen-II. After the screening is complete the examiner collects the Socioeconomic Data Collection Form from the parent and leaves the room to score the assessment and write recommendations. The examiner then returns to the clinic room to discuss the results with the parent/guardian.
Study NCT03313427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Early Intervention
Description: At the UCIN:~* Parental education to empower them on motor development and parent-infant relationship. Consisted on 6 sessions during the first weeks at the NICU.~* Tactile and kinaesthetic stimulation managed by parents. 2 times a day, 15 minutes each, during 10 days.~At home:~Psychomotor Development Program for the baby; comprised of different exercises, in different phases, depending on child maturation stage. Started after hospital discharge until 2 months corrected age.
Study NCT03313427 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: NICU usual care
Study NCT00890565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron
Description: Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3
Study NCT00890565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: granisetron
Description: Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3
Study NCT00890565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: granisetron
Description: Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3
Study NCT03368170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesdopetam (IRL790)
Description: Mesdopetam (IRL790) capsule
Study NCT03368170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mesdopetam (IRL790)
Description: Mesdopetam (IRL790) capsule
Study NCT00919035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: torisel
Description: Patients will receive Torisel 25 mg weekly. Treatment continues until disease progression, patient's withdrawal, unacceptable toxicity or the investigator's discretion